BR112018011994B1 - Derivados solúveis em água de compostos 3,5-difenil-diazólicos, seus usos, e composição - Google Patents

Derivados solúveis em água de compostos 3,5-difenil-diazólicos, seus usos, e composição Download PDF

Info

Publication number
BR112018011994B1
BR112018011994B1 BR112018011994-6A BR112018011994A BR112018011994B1 BR 112018011994 B1 BR112018011994 B1 BR 112018011994B1 BR 112018011994 A BR112018011994 A BR 112018011994A BR 112018011994 B1 BR112018011994 B1 BR 112018011994B1
Authority
BR
Brazil
Prior art keywords
disease
compound
compounds
amyloidosis
anle138b
Prior art date
Application number
BR112018011994-6A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112018011994A2 (pt
Inventor
Armin Giese
Felix Schmidt
Christian Griesinger
Andrei Leonov
Sergey Ryazanov
Original Assignee
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V
Armin Giese
Felix Schmidt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V, Armin Giese, Felix Schmidt filed Critical Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V
Publication of BR112018011994A2 publication Critical patent/BR112018011994A2/pt
Publication of BR112018011994B1 publication Critical patent/BR112018011994B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018011994-6A 2015-12-14 2016-12-14 Derivados solúveis em água de compostos 3,5-difenil-diazólicos, seus usos, e composição BR112018011994B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15199972 2015-12-14
EP15199972.9 2015-12-14
PCT/EP2016/081084 WO2017102893A1 (en) 2015-12-14 2016-12-14 Water-soluble derivatives of 3,5-diphenyl-diazole compounds

Publications (2)

Publication Number Publication Date
BR112018011994A2 BR112018011994A2 (pt) 2018-12-04
BR112018011994B1 true BR112018011994B1 (pt) 2022-07-19

Family

ID=54850017

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011994-6A BR112018011994B1 (pt) 2015-12-14 2016-12-14 Derivados solúveis em água de compostos 3,5-difenil-diazólicos, seus usos, e composição

Country Status (21)

Country Link
US (1) US10308671B2 (enExample)
EP (1) EP3390412B1 (enExample)
JP (1) JP6898931B2 (enExample)
KR (1) KR102671166B1 (enExample)
CN (1) CN108473516B (enExample)
AU (1) AU2016372408B2 (enExample)
BR (1) BR112018011994B1 (enExample)
CA (1) CA3008334C (enExample)
CL (1) CL2018001570A1 (enExample)
DK (1) DK3390412T3 (enExample)
ES (1) ES2873510T3 (enExample)
HU (1) HUE054815T2 (enExample)
IL (1) IL260011B (enExample)
MX (1) MX379522B (enExample)
NZ (1) NZ742979A (enExample)
PH (1) PH12018501276A1 (enExample)
PL (1) PL3390412T3 (enExample)
PT (1) PT3390412T (enExample)
RU (1) RU2764131C2 (enExample)
WO (1) WO2017102893A1 (enExample)
ZA (1) ZA201803865B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH713150A2 (fr) * 2016-11-23 2018-05-31 Eta Sa Mft Horlogere Suisse Mécanisme régulateur à résonateur rotatif à guidage flexible entretenu par un échappement libre à ancre.
US10368502B2 (en) 2017-09-25 2019-08-06 Multiple Energy Technologies Llc Bioceramic and carbon-based hydroponic systems, methods and devices
EP4368184A3 (en) 2019-11-19 2024-07-31 Modag GmbH Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
US20250161273A1 (en) * 2022-03-01 2025-05-22 Modag Gmbh Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use
CN115337301A (zh) * 2022-07-22 2022-11-15 汕头大学医学院第一附属医院 Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用
CN116399983B (zh) * 2023-06-09 2023-08-15 天津辰欣药物研究有限公司 一种利用gc-ms法检测二叔丁基氯甲基磷酸酯残留量的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
NZ564326A (en) * 2005-06-16 2010-01-29 Cv Therapeutics Inc Prodrugs of A2B adenosine receptor antagonists
EP2272822A4 (en) * 2008-03-31 2012-01-18 Renascience Co Ltd PLASMINOG ACTIVATOR-1 HEMMER
EP2687513B1 (en) * 2008-06-09 2020-12-02 Ludwig-Maximilians-Universität München Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
JP6069661B2 (ja) * 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
SMT201700306T1 (it) * 2012-06-08 2017-07-18 Theravance Biopharma R&D Ip Llc Inibitori di neprilisina

Also Published As

Publication number Publication date
CN108473516B (zh) 2021-06-18
RU2018125590A (ru) 2020-01-20
CA3008334C (en) 2024-01-02
ZA201803865B (en) 2019-04-24
DK3390412T3 (da) 2021-06-21
RU2764131C2 (ru) 2022-01-13
KR20180089511A (ko) 2018-08-08
PL3390412T3 (pl) 2021-10-25
CA3008334A1 (en) 2017-06-22
PH12018501276A1 (en) 2019-01-28
ES2873510T3 (es) 2021-11-03
IL260011B (en) 2021-12-01
PT3390412T (pt) 2021-06-22
US20180370997A1 (en) 2018-12-27
MX2018006877A (es) 2018-09-18
IL260011A (en) 2018-07-31
CL2018001570A1 (es) 2018-12-28
JP2019501167A (ja) 2019-01-17
EP3390412B1 (en) 2021-04-14
MX379522B (es) 2025-03-10
WO2017102893A1 (en) 2017-06-22
KR102671166B1 (ko) 2024-05-31
CN108473516A (zh) 2018-08-31
RU2018125590A3 (enExample) 2020-04-21
AU2016372408A1 (en) 2018-06-21
NZ742979A (en) 2022-05-27
US10308671B2 (en) 2019-06-04
JP6898931B2 (ja) 2021-07-07
BR112018011994A2 (pt) 2018-12-04
EP3390412A1 (en) 2018-10-24
HUE054815T2 (hu) 2021-10-28
AU2016372408B2 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
BR112018011994B1 (pt) Derivados solúveis em água de compostos 3,5-difenil-diazólicos, seus usos, e composição
JP6518270B2 (ja) Ｇｓｋ−３阻害剤としての新規チアジアゾリジンジオン
WO2018096504A1 (en) Cbd prodrugs, compositions, and methods of administering cbd and cbd prodrugs
JP2022513392A (ja) 活性分子送達のための胆汁酸及びそれらの誘導体の抱合体
BR112014007568B1 (pt) Composição farmacêutica sólida e seu processo de preparação
JP2015534990A (ja) 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法
CN111372579B (zh) 取代的苯基磺酰基苯基三唑硫酮和其用途
ES2770128T3 (es) Derivados de pirazol tricíclicos condensados útiles para modular los receptores farnesoide x
SA516380258B1 (ar) أملاح مقبولة صيدلانيا من متشاكلات بيرليندول للاستخدام في الدواء
AU2018205277B2 (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases
KR20050119104A (ko) 치환된 퀴놀린과 치환된 디페닐설폰을 함유하는 조성물과방법
US12251394B2 (en) Methods for the treatment of bladder cancer
JP6445046B2 (ja) １，１’−（１，６−ジオキソ−１，６−ヘキサンジイル）ビス−ｄ−プロリンのプロドラッグ
EP3534954A1 (en) Compounds for treatment of neurodegenerative diseases
US9809563B2 (en) Maleic acid salt of anti-prion compound, method for producing the same and pharmaceutical composition of the same
CN114401948A (zh) 用于改善认知功能和对抗物质成瘾的噻唑和二苯基取代的亚砜
US20240287108A1 (en) nSMASE2 INHIBITOR PRODRUGS WITH ENHANCED ORAL AND BRAIN EXPOSURES
ES2449640B1 (es) Compuestos para su uso en el tratamiento de la enfermedad de alzheimer
WO2018217138A1 (ru) Новый мультитаргетный препарат для лечения заболеваний у млекопитающих
HK40104521A (zh) 取代的萘基P38α丝裂原活化的蛋白激酶抑制剂

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2016, OBSERVADAS AS CONDICOES LEGAIS

B25G Requested change of headquarter approved

Owner name: ARMIN GIESE (DE) ; FELIX SCHMIDT (DE) ; MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE)

B25G Requested change of headquarter approved

Owner name: ARMIN GIESE (DE) ; FELIX SCHMIDT (DE) ; MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE)

B25A Requested transfer of rights approved

Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V (DE)

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE)

Free format text: RETIFICACAO DO DESPACHO ?(25.1) ? TRANSFERENCIA DE TITULAR? PUBLICADO NA RPI NO 2836, DE 13/05/2025, QUANTO AO ITEM ?(71) - DEPOSITANTE?.ONDE SE LE: ?MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V?LEIA-SE: ?MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.?